Clinical trials: Hidradenitis
Hidradenitis Suppurativa
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in areas of the skin such as under the breasts, under armpits, inner thighs, groin…
- Trial name
- Intrepid (NCT06468228)
- Testing
- Lutikizumab
- Where
- 279 sites in United States, Argentina and 42 more
- Volunteers
- 1,400 people
- Sponsor
- AbbVie
Hidradenitis Suppurativa
An Alternative Dose Interval Study in Participants With Hidradenitis Suppurativa Receiving Brodalumab
Phase 0 Study of an alternative dosing interval of Brodalumab in patients with moderate to severe Hidradenitis Suppurativa to identify biomarkers of disease activity and clinical response.
- Trial name
- NCT04249713
- Testing
- Brodalumab
- Where
- United States
- Sponsor
- Rockefeller University
Hidradenitis Suppurativa
Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
This is a study to evaluate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa.
- Trial name
- NCT06411379
- Testing
- Sonelokimab
- Where
- 106 sites in United States, Belgium and 10 more
- Volunteers
- 418 people
- Sponsor
- MoonLake Immunotherapeutics AG
Hidradenitis Suppurativa (HS)
The Safety and Efficacy of Roflumilast Foam in HS
This study investigates the efficacy of topical roflumilast foam in patients with HS.
- Trial name
- NCT07263230
- Testing
- Roflumilast 0.3% topical foam
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Beth Israel Deaconess Medical Center
Chronic Urticaria, Idiopathic, Hidradenitis
Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa
The study duration for an individual subject includes screening (14 days), the treatment period (28 days) and the observational follow-up period of 28 days, in total 70 days ± 6 days.
- Conditions
- Chronic Urticaria, Idiopathic, Hidradenitis, Hidradenitis Suppurativa
- Trial name
- NCT06555328
- Testing
- CSU lower dose treatment, CSU high dose treatment, CSU non responders IgE - high dose treatment
- Where
- 29 sites in United States, Bulgaria and 4 more
- Volunteers
- 73 people
- Sponsor
- InflaRx GmbH
Hidradenitis Suppurativa
To Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
The trial is a 12-week phase 2 study. Subjects will be given subcutaneous injections at weeks 0 (160mg), 2 (80mg), and then every other week (40mg) until week 12 in subjects with moderate to severe hidradenitis suppurativa.
- Trial name
- HIDRI2007 (NCT00827996)
- Testing
- adalimumab
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Florida Academic Dermatology Centers
Hidradenitis Suppurativa
Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
The purpose of this study is to explore whether BDB-001 Injection is effective and safe in the treatment of moderate to severe hidradenitis suppurativa(HS).
- Trial name
- NCT05093855
- Testing
- BDB-001 Injection
- Where
- 15 sites in China
- Volunteers
- 41 people
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
Hidradenitis Suppurativa
Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa
A study to assess the safety and efficacy of the IV drug infliximab for the treatment of hidradenitis suppurativa
- Trial name
- HS2006 (NCT00795574)
- Testing
- infliximab
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Florida Academic Dermatology Centers
Hidradenitis Suppurativa
Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients
The study evaluates the efficacy of an adapted antibiotherapy in Hurley stage 2 active Hidradenitis Suppurativa patients versus tetracycline derivative
- Trial name
- ABCESS2 (NCT05821478)
- Where
- 4 sites in France
- Volunteers
- 92 people
- Sponsor
- Institut Pasteur
Hidradenitis Suppurativa
A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)
The primary purpose of the study is to evaluate the effect of brensocatib compared with placebo.
- Trial name
- CEDAR (NCT06685835)
- Testing
- Brensocatib
- Where
- 72 sites in United States, Australia and 8 more
- Volunteers
- 214 people
- Sponsor
- Insmed Incorporated
Hidradenitis Suppurativa
Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Secukinumab.
This study will be conducted to address the lack of concrete data on the impact of pharmaceutical intervention on short-term patient satisfaction and quality of life (QoL) in patients with Hidradenitis Suppurativa (HS) in…
- Trial name
- NCT06785675
- Testing
- Secukinumab
- Where
- 4 sites in United Arab Emirates
- Volunteers
- 53 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa
Negative Pressure Wound Therapy With Instillation for Treatment of Hidradenitis Suppurativa
The current surgical management for severe Hidradenitis suppurativa (HS) involves wide excision of affected skin, resulting in a large soft tissue defect.
- Trial name
- HIDRA (NCT04325607)
- Testing
- Excision of HS followed by NPWTi, Excision of HS followed by NPWT
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- Royal Free Hospital NHS Foundation Trust
Hidradenitis Suppurativa
A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.
Hidradenitis suppurativa (HS) is a painful, long-term skin condition that causes abscesses and scarring on the skin.
- Trial name
- NCT03248531
- Testing
- Bimekizumab, Adalimumab
- Where
- 31 sites in United States, Australia and 6 more
- Volunteers
- 90 people
- Sponsor
- UCB Biopharma SRL
Hidradenitis Suppurativa, Quality of Life
Mindfulness Training Hidradenitis Suppurativa (HS)
The purpose of this research is to investigate the effectiveness of mindfulness training on the quality of life of Hidradenitis Suppurativa (HS) patients. HS can have a profound impact on quality of life.
- Trial name
- NCT05642039
- Testing
- Mindfulness Course, HS Educational Course
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Miami
Crohn Disease, Ulcerative Colitis
The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.
The purpose of the Phase IV study is to investigate the effects of both Volume and Citrate on Injection Site Pain (ISP), adherence, patient satisfaction, Quality of Life, and Disease Assessment in the Canadian Adalimumab Market.
- Conditions
- Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- EASE PAIN (NCT05913817)
- Testing
- AVT02 (Alvotech Biosimilar to Adalimumab)
- Where
- Canada
- Volunteers
- 324 people
- Sponsor
- Jamp Pharma Corporation
Hidradenitis Suppurativa
Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)
The purpose of this study was to demonstrate superiority of secukinumab at Week 16, based on Hidradenitis Suppurativa Clinical Response (HiSCR) rates versus placebo, along with the maintenance of efficacy of secukinumab at Week…
- Trial name
- SUNRISE (NCT03713632)
- Testing
- Secukinumab
- Where
- 108 sites in United States, Argentina and 30 more
- Volunteers
- 545 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa (HS)
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
A study to evaluate the safety and efficacy of treatment with adalimumab in adults with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- PIONEER II (NCT01468233)
- Testing
- adalimumab
- Volunteers
- 326 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hidradenitis Suppurativa
A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
The purpose of this study is to evaluate the safety of INCB054707 over an 8-week treatment period in men and women with moderate to severe hidradenitis suppurativa.
- Trial name
- NCT03607487
- Testing
- INCB054707
- Where
- 13 sites in Canada, Denmark and 1 more
- Volunteers
- 35 people
- Sponsor
- Incyte Corporation
Hidradenitis Suppurativa
A National Registry For Patients With Hidradenitis Suppurativa
The goal of this study is to get a better understanding of the skin condition, Hidradenitis Suppurativa, and to find out how the disease affects quality of life.
- Trial name
- NCT03289585
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Montefiore Medical Center
Hidradenitis Suppurativa (HS)
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.
- Trial name
- STOP-LTR (NCT06855498)
- Testing
- povorcitinib
- Where
- 296 sites in United States, Argentina and 18 more
- Volunteers
- 600 people
- Sponsor
- Incyte Corporation